Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 17

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 17
---
 document incorporated herein by reference might not occur. Investors are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date of this prospectus or the date of the document incorporated by reference in this prospectus. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

| 9 |

<div align='center'>CAPITALIZATION</div>

Our capitalization will be set forth in a prospectus
supplement to this prospectus or in a Report on Form 6-K subsequently furnished to the SEC and specifically incorporated herein by reference.

| 10 |

<div align='center'>USE OF PROCEEDS</div>

Unless otherwise indicated
in the applicable prospectus supplement, we intend to use any net proceeds from the sale of securities under this prospectus for general
corporate purposes, including development of our clinical and preclinical programs, other research and development costs, acquisitions
of development or commercial assets, working capital and capital expenditures. We have not determined the amounts we plan to spend on
any of the areas listed above or the timing of these expenditures. As a result, our management will have broad discretion to allocate
the net proceeds, if any, we receive in connection with securities offered pursuant to this prospectus for any purpose. Pending application
of the net proceeds as described above, we may initially invest the net proceeds in short-term, investment-grade and interest-bearing
securities.

| 11 |

<div align='center'>PLAN OF DISTRIBUTION</div>

We may offer securities under
this prospectus from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of
these methods. We may sell the securities (1) through underwriters or dealers, (2) through agents or (3) directly to one or more purchasers,
or through a combination of such methods. We may distribute the securities from time to time in one or more transactions at:

| · | a fixed price or prices, which may be changed from time to time; |

| · | market prices prevailing at the time of sale; |

| · | prices related to the prevailing market prices; or |

| · | negotiated prices. |

We
may directly solicit offers to purchase the